UB Paderborn / Katalog / Suche / in CDI

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

PloS one, 2018-10, Vol.13 (10), p.e0204973

2018

Volltextzugriff (PDF)

A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design

Trials, 2022-03, Vol.23 (1), p.193-193, Article 193

2022

Volltextzugriff (PDF)

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk

Journal of clinical oncology, 2020-08, Vol.38 (24), p.2762-2772

2020

Volltextzugriff (PDF)

Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy

Journal of clinical oncology, 2022-09, Vol.40 (27), p.JCO2100277-3204

2022

Volltextzugriff (PDF)

Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis

Journal of clinical oncology, 2022-07, Vol.40 (19), p.JCO2101958-2162

2022

Volltextzugriff (PDF)

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

Genome Biology, 2015-05, Vol.16 (1), p.107-107, Article 107

2015

Volltextzugriff (PDF)

p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

British journal of cancer, 2024-03, Vol.130 (4), p.613-619

2024

Volltextzugriff (PDF)

Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity

Drug safety, 2020-10, Vol.43 (10), p.1045-1055

2020

Volltextzugriff (PDF)

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

BMC cancer, 2010-05, Vol.10 (1), p.222-222, Article 222

2010

Volltextzugriff (PDF)

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Journal of neuro-oncology, 2009-07, Vol.93 (3), p.379-384

2009

Volltextzugriff (PDF)

Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France

Breast (Edinburgh), 2016-12, Vol.30, p.73-79

2016

Volltextzugriff (PDF)

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines

Cancer research (Chicago, Ill.), 1997-01, Vol.57 (2), p.300-303

1997

Volltextzugriff (PDF)

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas

Journal of clinical oncology, 2010-10, Vol.28 (28), p.e541-e542

2010

Volltextzugriff (PDF)

Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy

Anti-cancer drugs, 2011-11, Vol.22 (10), p.1020-1023

2011

Volltextzugriff (PDF)

Questions prompt lists used by palliative care teams help trigger discussions on prognosis and end-of-life issues with advanced cancer patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.12110-12110

2020

Volltextzugriff (PDF)

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Journal of neuro-oncology, 2009-07, Vol.93 (3), p.385-385

2009

Volltextzugriff (PDF)

Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA -mutant advanced breast cancer: Data from the French early access program

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1064-1064

2021

Volltextzugriff (PDF)

Abstract P2-13-27: Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-27

2022

Volltextzugriff (PDF)

Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13067-e13067

2023

Volltextzugriff (PDF)

Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.546-546

2023

Volltextzugriff (PDF)

Tolerance of concurrent CDK inhibitor and radiation therapy in metastatic breast cancer patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e12598-e12598

2020

Volltextzugriff (PDF)

Abstract P1-18-19: Long term results with everolimus in advanced hormone receptor positive breast cancer in a multicenter national real world observational study (ESME)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-19

2022

Volltextzugriff (PDF)

Docetaxel and ovarian cancer

Expert review of obstetrics & gynecology, 2007-11, Vol.2 (6), p.719-724

2007

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design

Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk

Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy

Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study

Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas

Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy

Questions prompt lists used by palliative care teams help trigger discussions on prognosis and end-of-life issues with advanced cancer patients

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA -mutant advanced breast cancer: Data from the French early access program

Abstract P2-13-27: Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study

Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity

Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial

Tolerance of concurrent CDK inhibitor and radiation therapy in metastatic breast cancer patients

Abstract P1-18-19: Long term results with everolimus in advanced hormone receptor positive breast cancer in a multicenter national real world observational study (ESME)

Docetaxel and ovarian cancer

Aktive Filter

Suchergebnisse filtern